What changed, and when

BioNTech DualityBio BNT324 Phase 3 mCRPC announced, with planned enrollment of 736 and a planned start in March 2026. (Fierce Biotech: “BioNTech’s B7-H3 ADC hits ph. 3 at half the size of Merck’s”, BioNTech trial listing: BNT324-03)

The positioning is explicitly “lean versus Merck–Daiichi,” whose IDeate-Prostate01 plans ~1,440 patients in a similar docetaxel comparator design. (Merck press release: IDeate-Prostate01 initiated)

60-second thesis frame

This is a bet that B7-H3 targeting can translate into a registrational rPFS and OS benefit in post-ARPI, pre-taxane mCRPC with a smaller Phase 3 than the leading rival, which, if true, compresses time-to-answer and burn, but raises power, endpoint-behavior, and cross-trial-comparability risk. The confidence hinge is whether the updated Phase 1/2 signal in heavily pretreated mCRPC (median rPFS 11.3 months, median OS 22.5 months as described in secondary reporting, and tied to ASCO GU materials) reflects a robust effect or a selection-rich cohort that will regress in a broader randomized setting. (Fierce Biotech: Phase 1/2 mCRPC stats and Phase 3 sizing, ASCO abstract PDF: DB-1311/BNT324 in mCRPC)
Competitively, the “Merck–Daiichi” B7-H3 ADC class has already faced safety scrutiny in at least one Phase 3 setting (ILD-related events in IDeate-Lung02), which can shift investor perception of class risk even when targets, payloads, and populations differ. (Fierce Biotech: partial hold, ILD events)

The seven diligence questions

Clinical

• Does BNT324 show a clear, reproducible advantage in rPFS and OS over docetaxel in the exact Phase 3 population (post-ARPI, pre-taxane for mCRPC), not just in later-line responders? (BioNTech trial listing: BNT324-03)
• What is the class-relevant tox profile to watch in prostate, especially ILD/pneumonitis, cytopenias, ocular, and neuropathy signals, and what are the protocol-level mitigations (dose mods, imaging cadence, adjudication)? (Mechanism context via competitor disclosure, not implying sameness) (Merck press release: IDeate-Prostate01 and B7-H3 background, Fierce Biotech: ILD events in rival program)

Payer or Access

• If the trial wins, where does BNT324 sit relative to ARPIs, PARP inhibitors (subset), radioligands (Pluvicto), and taxanes in real-world pathways, and what step edits should you expect in US commercial and EU single-payer systems? (Benchmark against current “docetaxel baseline” positioning) (BioNTech trial listing: comparator and population)
• Is there a plausible biomarker or clinical-enrichment strategy (B7-H3 expression, ctDNA features, prior Pluvicto failure) that can support pricing and access narratives, or does it remain a broad, expensive line-extension problem? (Fierce Biotech: Pluvicto-exposed subgroup callout)

Ops or Adoption

• Can BioNTech execute prostate oncology commercialization credibly (KOL activation, community urology uptake, AE management pathways) given its legacy strength elsewhere, and what is the concrete launch sequence if Phase 3 reads out positive? (Inference, check IR/oncology buildout signals) (Merck press release as “incumbent execution bar”)
• Manufacturing and CMC: what is the payload, DAR consistency, and capacity plan for a potentially high-volume solid tumor indication, and does it introduce approval or supply fragility?

Competitive

• How much of the “lean trial” advantage is structural (larger effect size, cleaner endpoints) versus fragile (underpowered in heterogeneous mCRPC), especially against a larger, parallel docetaxel-controlled rival program? (Fierce Biotech: 736 vs 1,440 framing, Merck press release: 1,440 patients)

Team or Cap table

• Deal alignment: what are the economics and control terms with DualityBio for BNT324 in prostate (territory rights, profit split, opt-ins), and do incentives maximize speed plus quality of evidence?

Red flags

• The Phase 3 is sized “lean,” so a smaller-than-expected effect size or higher-than-expected event noise could produce an ambiguous readout, even if the drug is clinically useful. (Fierce Biotech: “lean strategy” and Phase 3 sizing)
• Any emerging ILD/pneumonitis signal that forces monitoring burdens, dose reductions, or holds, because investors may extrapolate “class risk” from adjacent B7-H3 ADC programs. (Fierce Biotech: partial hold due to ILD events)
• If docetaxel control performance is stronger than expected (or post-progression therapies differ materially by region), OS could be harder to separate, weakening the “practice-changing” argument even with rPFS movement. (BioNTech trial listing: dual primary endpoints rPFS and OS)

Next catalyst

Phase 3 initiation milestones for BNT324-03 (first patient dosed, site activation pace) in the March–June 2026 window, plus any additional ASCO/EUA updates that clarify durability and safety in the mCRPC subset. (BioNTech trial listing: Mar 2026 start window, Fierce Biotech: ASCO GU context)

FAQ

• What exactly changed by BioNTech and DualityBio’s B7-H3 ADC Phase 3 news on 27 Feb 2026, and why does it matter for mCRPC?
  BioNTech and DualityBio disclosed a Phase 3 plan for BNT324 (DB-1311) in metastatic castration-resistant prostate cancer with a targeted enrollment of 736, framed as a faster, smaller pivotal test than the leading rival program. (Fierce Biotech: Feb 27, 2026 piece, BioNTech trial listing: BNT324-03)
  If the effect holds in a randomized setting, the smaller trial could shorten time-to-decision, but it also concentrates statistical and execution risk.
• What are the formal endpoints and comparator after the 27 Feb 2026 Phase 3 disclosure, and how comparable is it to the Merck–Daiichi rival?
  BioNTech’s BNT324-03 Phase 3 uses docetaxel plus prednisone/prednisolone as the SoC comparator and targets rPFS and OS as the main outcomes. (BioNTech trial listing: BNT324-03)
  Merck–Daiichi’s IDeate-Prostate01 similarly compares ifinatamab deruxtecan versus docetaxel plus corticosteroid with dual primary endpoints of rPFS and OS, enabling cleaner “design-level” comparisons even though molecules and populations can still differ. (Merck press release: IDeate-Prostate01)
• Which data motivated BioNTech’s move into Phase 3 as reported on 27 Feb 2026, and what should you sanity-check?
  Secondary reporting cites updated Phase 1/2 outcomes in heavily pretreated mCRPC, including median rPFS of 11.3 months and median OS of 22.5 months, with a highlighted subgroup previously treated with Pluvicto. (Fierce Biotech: efficacy figures and subgroup)
  You should sanity-check cohort size, censoring, follow-up length, and how “evaluable” patients were defined in the ASCO abstract materials. (ASCO abstract PDF: DB-1311/BNT324)
• What safety issues matter most when thinking about B7-H3 ADCs after the 27 Feb 2026 BioNTech Phase 3 move?
  Even though safety is molecule-specific, investors will watch pneumonitis/ILD risk closely because a related B7-H3 ADC program reported grade 5 ILD events leading to pauses and a partial hold in one Phase 3 trial. (Fierce Biotech: ILD and partial hold)
  In prostate, the practical question becomes whether monitoring and management requirements are “clinic-acceptable” in community settings, not only whether events occur.
• How should you think about trial scale and timelines after the 27 Feb 2026 disclosure?
  BioNTech’s public trial listing indicates an estimated enrollment of 736 and an estimated study window from March 2026 to February 2031, which implies a multi-year time-to-final OS maturity unless interim looks or accelerated paths emerge. (BioNTech trial listing: dates and enrollment)
  Merck–Daiichi’s IDeate-Prostate01 plans ~1,440 patients, which can increase power but can also elongate enrollment and cost, so “faster answer” is not guaranteed for either program. (Merck press release: 1,440 patients)

Publisher / Disclosure

Publisher: LucidQuest Ventures Ltd. Produced: 28 Feb 2026, 20:14 London. Purpose: general and impersonal information. Not investment research or advice, no offer or solicitation, no suitability assessment. UK: directed at investment professionals under Article 19(5) and certain high-net-worth entities under Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this. Sources and accuracy: public sources believed reliable, provided “as is,” may change without notice. No duty to update. Past performance is not reliable. Forward-looking statements carry risks. Methodology: questions-first framework using public sources. No conflicts. Authors do not hold positions unless stated. © 2026 LucidQuest Ventures Ltd.

Entities / Keywords

BioNTech; DualityBio; BNT324; DB-1311; B7-H3; antibody-drug conjugate; ADC; mCRPC; metastatic castration-resistant prostate cancer; docetaxel; prednisone; prednisolone; rPFS; overall survival; ARPI; androgen receptor pathway inhibitor; Pluvicto; radioligand therapy; Merck; Daiichi Sankyo; ifinatamab deruxtecan; I-DXd; IDeate-Prostate01; IDeate-Lung02; ILD; pneumonitis; ASCO GU; KOLs; community urology; CMC; DAR

Find more Lucid Diligence Briefs here.